Literature DB >> 24998563

Cervical cancer gene therapy by gene loaded PEG-PLA nanomedicine.

Bo Liu1, Shu-Mei Han, Xiao-Yong Tang, Li Han, Chang-Zhong Li.   

Abstract

BACKGROUND AND AIMS: Advances in the treatment of cervical cancer over the last decade have predominantly involved the development of genes directed at molecular targets. Gene therapy is recognized to be a novel method for the treatment of cervical cancer. Genes can be administered into target cells via nanocarriers. This study aimed to develop systemically administrable nano-vectors. Floate (Fa) containing gene loaded nanoparticles (NPs) could target HeLa human cervical cancer cells through combination with receptors on the cells to increase the nuclear uptake of genetic materials.
METHODS: Fa was linked onto Poly (ethylene glycol)-b-poly (D, L-lactide) (PEG-PLA) to form Fa-PEG-PLA, and the resulting material was used to load plasmids of enhanced green fluorescence protein (pEGFP) to obtain gene loaded nanoparticles (Fa-NPs/DNA). Physical-chemical characteristics, in vitro release and cytotoxicity of Fa-NPs/DNA were evaluated. The in vitro transfection efficiency of Fa-NPs/ DNA was evaluated in HeLa cells and human umbilical vein endothelial cells (HUVEC). PEG-PLA without Fa was used to load pEGFP from NPs/DNA as a control.
RESULTS: Fa-NPs/DNA has a particle size of 183 nm and a gene loading quantity of 92%. After 72h of transfection, Fa-NPs/DNA displayed over 20% higher transfection efficiency than NPs/DNA and 40% higher than naked DNA in HeLa cells. However, in HUVECs, no significant difference appeared between Fa-NPs/DNA and NPs/DNA.
CONCLUSIONS: Fa-PEG-PLA NPs could function as excellent materials for gene loading. This nano-approach could be used as tumor cell targeted medicine for the treatment of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24998563     DOI: 10.7314/apjcp.2014.15.12.4915

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

Review 1.  Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.

Authors:  Ekati Drakopoulou; Nicholas P Anagnou; Kalliopi I Pappa
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 2.  Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer.

Authors:  Loredana Maria Himiniuc; Bogdan Florin Toma; Razvan Popovici; Ana Maria Grigore; Alexandru Hamod; Constantin Volovat; Simona Volovat; Irina Nica; Decebal Vasincu; Maricel Agop; Mihaela Tirnovanu; Lacramioara Ochiuz; Anca Negura; Mihaela Grigore
Journal:  J Immunol Res       Date:  2022-05-04       Impact factor: 4.493

3.  Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer.

Authors:  Bo Liu; Li Han; Junyan Liu; Shumei Han; Zhen Chen; Lixi Jiang
Journal:  Int J Nanomedicine       Date:  2017-01-31

Review 4.  Targeted Gene Delivery Therapies for Cervical Cancer.

Authors:  Ángela Áyen; Yaiza Jiménez Martínez; Houria Boulaiz
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 5.  Possible role of nanocarriers in drug delivery against cervical cancer.

Authors:  Swati Gupta; Manish K Gupta
Journal:  Nano Rev Exp       Date:  2017-07-07

6.  ERK-mediated autophagy promotes inactivated Sendai virus (HVJ-E)-induced apoptosis in HeLa cells in an Atg3-dependent manner.

Authors:  Tao Wang; Ning Yu; Miao Qian; Jie Feng; Shuyang Cao; Jun Yin; Quan Zhang
Journal:  Cancer Cell Int       Date:  2018-12-04       Impact factor: 5.722

7.  Overexpression of mircoRNA-137 inhibits cervical cancer cell invasion, migration and epithelial-mesenchymal transition by suppressing the TGF-β/smad pathway via binding to GREM1.

Authors:  Hui Miao; Nuan Wang; Lin-Xin Shi; Zheng Wang; Wen-Bo Song
Journal:  Cancer Cell Int       Date:  2019-05-23       Impact factor: 5.722

8.  Knockdown of Wip1 Enhances Sensitivity to Radiation in HeLa Cells Through Activation of p38 MAPK.

Authors:  Hong-Yong Wang; Zhong-Shan Liu; Ling Qiu; Jie Guo; Yun-Feng Li; Jun Zhang; Tie-Jun Wang; Xiao-Dong Liu
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.